| Question 1: Which of the following parameters have been derived from clinical outcome data? |
| Reference: | Grassberger, C., and H. Paganetti. "Methodologies in the modeling of combined chemo-radiation treatments." Physics in Medicine & Biology 61.21 (2016): R344. |
| Choice A: | Optimal drug dosing schedules |
| Choice B: | General radio-sensitization factor (x*D) |
| Choice C: | Differential cell cycle drug- and radiation sensitivity |
| Choice D: | Radiation equivalent cell kill by drug |
| Choice E: | B and E. |
| Question 2: Which of the following constitute the main challenges when modeling molecularly targeted agents compared to traditional chemotherapy based on clinical data? |
| Reference: | Zhao, Boyang, Michael T. Hemann, and Douglas A. Lauffenburger. "Modeling tumor clonal evolution for drug combinations design." Trends in cancer 2.3 (2016): 144-158. |
| Choice A: | Longer time scales in administration of targeted agents |
| Choice B: | Mechanisms of action and their differences not well understood |
| Choice C: | Genetically distinct subpopulations with great differential in terms of sensitivity (sensitive – resistant) |
| Choice D: | Patient response more unpredictable with targeted agents |
| Choice E: | A and C. |
| Question 3: Physical processes in cancer are important, including: |
| Reference: | Mechanistic patient-specific predictive correlation of tumor drug response with microenvironment and perfusion measurements. J Pascal, EL Bearer, Z Wang, EJ Koay, SA Curley, V Cristini, Proceedings of the National Academy of Sciences 110 (35), 14266-14271 |
| Choice A: | Perfusion of drug molecules and cell substrates |
| Choice B: | Cell-cell and cell-stroma mechanical interactions |
| Choice C: | Drug and nanocarrier specific and nonspecific interactions with endothelium |
| Choice D: | All of the above |
| Question 4: Physical processes do not appear in vitro because of: |
| Reference: | Integrated nanotechnology platform for tumor-targeted multimodal imaging and therapeutic cargo release. H Hosoya, AS Dobroff, WHP Driessen, V Cristini, LM Brinker, FI Staquicini, ... Proceedings of the National Academy of Sciences 113 (7), 1877-1882 |
| Choice A: | Absence of transport gradients of drug and cell substrates |
| Choice B: | Cells do not interact |
| Choice C: | Cells do not uptake |
| Choice D: | Cells do not move |
| Question 5: Biomechanical model-based deformable image registration (DIR) has the potential to be more accurate than intensity-based DIR when the images present no or few other features than the boundaries of the structure to register: |
| Reference: | Velec, Michael et al. “Utility and validation of biomechanical deformable image registration in low-contrast images” Practical Radiation Oncology, Volume 5 , Issue 4 , e401 - e408 |
| Choice A: | True |
| Choice B: | False |
| Question 6: Considering organs with uniform or spatially heterogenous elastic properties for biomechanical model-based image registration has always been found to have low impact on registration accuracy: |
| Reference: | Savamati, Navid et al. “Effect of material property heterogeneity on biomechanical modeling of prostate under deformation.” Physics in Medicine & Biology, Volume 60, Number 1 |
| Choice A: | True |
| Choice B: | False |
